Distalmotion, Revival Healthcare Capital and 415 CAPITAL announce the closing of a USD 90 million Series E financing round to accelerate the adoption of Distalmotion’s surgical robot Dexter. The investment follows Dexter’s successful initial clinical use and supports Distalmotion’s international commercial scaling. Distalmotion is based at Biopole – Lausanne. Congrats to the entire team.
